A CNS CRO is a laboratory that specializes in neurological diseases. It offers a wide range of proprietary animal and cell-base models for preclinical testing of test compounds. It also offers in vivo models of conditions such as stroke, epilepsy, and schizophrenia. Its goal is to help companies develop better medications for patients suffering from these conditions.
A CNS CRO is a research company that develops mathematical models to predict disease. These models replicate the disease process from its early onset to its progression through a series of events. These models can be use to predict the progressive degeneration of the central nervous tissue. This information can be valuable for drug development and discovery.
CNS CRO is a neurological disease specialty laboratory
CNS CRO is a neurological disease specialized laboratory offering a range of pre-clinical and animal models for research. The company provides unique animal models and pre-clinical contract research services, providing focus, expertise and quality customer experience to clients. The company’s services are flexible and innovative, making them ideal for early stage drug development. These services help companies develop new therapies for neurological diseases and improve current treatments.
Investing in a CNS CRO can help companies develop and evaluate new therapies for neurodegenerative diseases. These diseases can be complex and time-consuming, but partnering with a CNS CRO can help companies overcome these challenges. One such CNS CRO is Vial. It provides comprehensive services, including a broad menu of inflammatory markers and a deep network of laboratory partners that can support CNS studies.
It offers a range of proprietary cell-base and animal models for preclinical evaluation of test compounds
Customize testing services are available for test compounds. Custom ELISA development and electrochemiluminescence multiplex formats are available for testing. These services allow for the development of tests that are uniquely tailor to the needs of a specific drug candidate.
Yumanity Therapeutics utilizes a proprietary platform to identify and develop compounds for previously unknow disease targets. These compounds target misfold proteins in the body and can correct cellular toxicity. For example, the company is advancing a lead program to correct toxicity cause by a-synuclein, a protein link to Parkinson’s disease. In addition, the company is identifying compounds for Alzheimer’s disease and ALS.
Customize testing can be challenging. For instance, highly specialize treatment areas may have limit investigators. This makes it essential to create specialize test compounds to make sure that the treatment is effective before launching into the clinical trial phase.
It has a global network
CNS CRO is a new addition to Vial CRO’s global network of early to late-stage clinical trial centres. The company plans to use this acquisition to strengthen its biopharma offering throughout the Asia-Pacific region. CNS employs more than 140 people across the region and is currently a leader in early-phase non-oncology clinical trials. In addition to Australia and New Zealand, CNS has offices in the United States and Europe.
CNS is a full-service CRO base in Australia that offers integrate development services. CNS recently acquire the business assets of BELTAS, a New Zealand-base CRO. The contracts and staff were transfer to CNS at the end of 2012. BELTAS will continue to offer GCP training in New Zealand.
Clinical Network Services, an integrated service group, has offices in Australia, New Zealand, the United Kingdom and the United States. The company’s team of scientists and regulatory experts work together to help early-stage biotechnology companies advance their products to clinical trials. They have a strong team of biometrics experts and a dedicate clinical services team. In Australia and New Zealand, clinical trials and drug registration are facilitate by pragmatic regulatory environments.
It has in vivo models for stroke, epilepsy and schizophrenia
The CNS CRO develops in vivo models of neurological disorders to predict the clinical course of these diseases. These models mimic the disease process from its earliest onset through the cascade of events. This helps companies better understand the behavioral characteristics of these diseases and the potential therapeutic benefits of certain drugs.
Recent advances in animal modeling for epilepsy and poststroke seizures have result in improvements in our understanding of the disease. These models help us to understand the early and late stages of epileptogenesis and stroke. As a result, drug development can be accelerate faster and more effectively. For example, in vivo models can improve the design of clinical trials and allow scientists to compare the effectiveness of different treatments.
Dr. Jeff Mulchahey joins CNS CRO
CNS CRO Clinilabs is pleased to welcome Dr. Jeff Mulchahey as Chief Development Officer. Mulchahey brings over 20 years of experience in the drug development field and has particular expertise in the CNS therapeutic area. He most recently served as Senior Vice President of Clinical Development for Syneos Health, where he was responsible for the clinical development portfolio in the neurosciences. His experience in CNS research and development includes leading more than 40 multinational phase 2 and phase 3 trials, many in Asia.
Read also: Examples of a Contract Research Organization
Vial acquires CNS CRO
Vial CRO is expanding its biopharma business in the U.S. by acquiring a South Carolina-based CNS CRO. The deal brings more than 300 employees and expertise in the field. The company is primarily focused on clinical trials for oncology, hematology, infectious disease, and CNS therapies. The acquisition will complement Vial CRO’s existing hundreds of site network in Asia-Pacific and the U.S.
The acquisition of NCGS will allow Vial CRO to expand its US and Asian client base. NCGS focuses on complex clinical areas, including oncology, hematology, and infectious disease. Its founder and CEO, Nancy Snowden, has worked with Vial CRO for more than two decades. The merger will also give Vial CRO Health Holdings a scalable platform for clinical trials across Asia.
Vial CRO has about 400 employees across the Asia-Pacific region. It also has business development offices in the U.S., which will enable it to provide global services. Its specialty CRO, Clinical Network Services, has 140 employees in Australia, New Zealand, and the US. It also offers biodesk capabilities, which can help clients with early stage product development. It also provides FDA/EMA regulatory consulting and toxicology advice.
With its presence in the Asia-Pacific region, Vial CRO has a competitive advantage when it comes to supplying global services. It has deep relationships with leading investigators in the region. This unique advantage allows Vial CRO to develop regional CRO capabilities while providing global regulatory services.
Nasson Science expands into other diseases
The Nasson Science CNS CRO has recently expanded its services beyond CNS diseases to other diseases. With expertise in animal models of CNS diseases, Nasson is well positioned to tackle problems in autoimmune and metabolic disorders as well as cancer. Its expansion into other diseases will enable it to better serve clients worldwide.
The company has a unique management structure. Its Chief Scientific Officer (CSO) Dr. Jonathan Freeman has 25 years of experience in developing new CNS drugs. Prior to Nasson, he served as Leiter of preclinical projects for the CHDI Foundation in the United States. He also held positions at Galileo Pharma and Vertex Pharmaceuticals.
Nasson Science CNS CRO’s capabilities span all phases of clinical trials. The company also specialises in early-phase non-oncology clinical trials in Australia and New Zealand. In addition, it has acquired the Australasian specialist CRO Clinical Network Services. This acquisition will enable both companies to expand their services into biopharma. The two companies will maintain separate brands and identities. The combined company will provide clients with access to the Asia-Pacific market and BioDesk’s clinical monitoring expertise.
Nasson Science has branched out into other diseases after focusing on cancer. The company’s platform is designed to facilitate a range of drug delivery routes and also accommodate preclinical proof-of-concept testing of medical devices. The company’s state-of-the-art technologies enable rapid testing of preclinical drug candidates.
QPS is a CNS CRO
QPS is a full-service contract research organization that specializes in the clinical and preclinical research of CNS and mental disorders. It offers highly predictive disease models, and has experience in studies for biopharmaceutical companies of all sizes. It also offers services in translational medicine and toxicology.
QPS is expanding its capabilities in central nervous system drug research and development. Its acquisition of JSW Life Sciences in Austria will enhance its Phase II-IV drug development capabilities and increase market share in Central and Eastern Europe. It will also strengthen QPS Netherlands’ late-stage site-monitoring capabilities in Central and Eastern Europe.
QPS is an award-winning global CRO that offers services for discovery, preclinical and clinical drug development. Its mission is to accelerate breakthroughs in pharmaceuticals. It works with biotech and pharmaceutical companies to develop novel drugs. QPS acquires promising drug compounds from small biotech firms and develops them into candidate drugs. They then undergo rigorous testing and are evaluated for approval by the FDA.
QPS is a full-service GLP/GCP-compliant CRO that specializes in clinical trials. It has a long track record of high-quality study data, and its site management & monitoring teams have years of experience. The firm also has extensive experience in rare diseases.
Nasson Science has in vivo models for stroke, epilepsy and schizophrenia
To understand the mechanisms of stroke, epilepsy and schizophrenia, we must first understand how these disorders affect the brain. During a stroke, the brain is damaged and suffers massive neuronal loss. In addition, the brain’s ability to regenerate new neurons is compromised. Consequently, seizures may result if the newly generated neural network experiences abnormal discharge. We can study stroke-like injuries in a laboratory setting by using in vivo models.
In vivo models are an excellent way to understand neurological disorders and identify new therapeutic targets. In stroke, the hypothalamic-pituitary-adrenal (HPA) axis is activated, which increases levels of the stress hormone cortisol, which is neurotoxic and can affect glucose metabolism in the brain. Additionally, cortisol increases the risk for epileptic seizures. Furthermore, acute disorder is associated with increased glutamate receptor levels in neurons, which are located in the postsynaptic membrane.
These studies also use population-based cohorts, which exclude subjects with psychiatric history prior to epilepsy to minimize potential confounders. A recent study confirmed the findings from previous studies, extending the previous studies. For the current study, the authors of the study excluded subjects with psychiatric histories before seizure onset.
